Ligand Pharma (LGND) Tops Q3 EPS by 40c; offers guidance

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.02, $0.40 better than the analyst estimate of $0.62. Revenue for the quarter came in at $32.9 million versus the consensus estimate of $27.22 million.

GUIDANCE:

Ligand Pharma sees FY2023 EPS of $5.25-$5.40, versus the consensus of $5.04. Ligand Pharma sees FY2023 revenue of $126-129 million, versus the consensus of $126.5 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• Corpay agrees to $100M FTC settlement over marketing practices